Phaseline

Companies › Curemark

Curemark: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Psychiatry; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CM-AT
Proteolytic enzyme (chymotrypsin)
–Phase 3AutismJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02649959CM-ATPhase 3AutismPsychiatryJan 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Emalex Biosciences Boston Medical Group Transcend Therapeutics Gedeon Richter Cybin IRL

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.